16 patents
Utility
DARPin based multi-specific t-cell engagers
5 Dec 23
The present invention relates to recombinant multi-specific proteins comprising binding agents with binding specificity for different targets, such as, e.g.
Nina Reschke, Sebastian Grimm, Christian Reichen, Bernd Schlereth, Victor Levitsky, Matteo Bianchi
Filed: 9 Mar 22
Utility
Designed Ankyrin Repeat Domains with Altered Surface Residues
26 Oct 23
The present invention relates to designed ankyrin repeat domains with altered surface residues, as well as to proteins comprising such a designed ankyrin repeat domain, nucleic acids encoding such domains or proteins, methods of preparing such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.
Hans Kaspar BINZ, Johannes SCHILLING, Patrik FORRER, Victor LEVITSKY, Natalia VENETZ, Marcel WALSER
Filed: 12 Jan 23
Utility
Recombinant Peptide-mhc Complex Binding Proteins and Their Generation and Use
3 Aug 23
The present invention relates to a method of producing recombinant binding proteins with binding specificity for a peptide-MHC (pMHC) complex.
Victor LEVITSKY, Natalia VENETZ, Marcel WALSER, Hans Kaspar BINZ, Johannes SCHILLING, Patrik FORRER
Filed: 24 Feb 23
Utility
NOVEL DARPin BASED MULTI-SPECIFIC T-CELL ENGAGERS
23 Feb 23
The present invention relates to recombinant multi-specific proteins comprising binding agents with binding specificity for different targets, such as, e.g.
Nina RESCHKE, Sebastian GRIMM, Christian REICHEN, Bernd SCHLERETH, Victor LEVITSKY, Matteo BIANCHI
Filed: 9 Mar 22
Utility
Designed ankyrin repeat domains with altered surface residues
14 Feb 23
The present invention relates to designed ankyrin repeat domains with altered surface residues, as well as to proteins comprising such a designed ankyrin repeat domain, nucleic acids encoding such domains or proteins, methods of preparing such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.
Hans Kaspar Binz, Johannes Schilling, Patrik Forrer, Victor Levitsky, Natalia Venetz, Marcel Walser
Filed: 12 Aug 21
Utility
Recombinant Peptide-mhc Complex Binding Proteins and Their Generation and Use
9 Feb 23
The present invention relates to a method of producing recombinant binding proteins with binding specificity for a peptide-MHC (pMHC) complex.
Victor LEVITSKY, Natalia VENETZ, Marcel WALSER
Filed: 11 Dec 20
Utility
Ankyrin repeat binding proteins and their uses
11 Oct 22
The present invention relates to recombinant binding proteins comprising one or more designed ankyrin repeat domains with binding specificity for coronavirus spike proteins, nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of coronavirus diseases, particularly diseases caused by SARS-CoV-2.
Patrick Amstutz, Valerie Perrine Calabro, Marcel Walser
Filed: 6 May 21
Utility
Designed ankyrin repeat proteins binding to hepatocyte growth factor
27 Sep 22
New designed ankyrin repeat proteins with binding specificity for HGF are described, as well as nucleic acids encoding such HGF binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.
Gaby Tresch, Talitha Bakker, Douglas Phillips, Frieder W. Merz, Kaspar H. Binz
Filed: 2 Jun 14
Utility
Recombinant 4-1BB Binding Proteins and Their Use
22 Sep 22
The present disclosure relates to recombinant binding proteins comprising a designed ankyrin repeat domain with binding specificity for 4-1 BB (CD 137).
Christian REICHEN, Alexander LINK, Julia HEPP, Victor LEVITSKY
Filed: 3 Jun 20
Utility
Recombinant Fap Binding Proteins and Their Use
4 Aug 22
The present disclosure relates to recombinant binding proteins comprising a designed ankyrin repeat domain with binding specificity for fibroblast activation protein (FAP).
Ulrike FIEDLER, Clara METZ, Misha Roland MULLER, Dan SNELL
Filed: 3 Jun 20
Utility
Novel Ankyrin Repeat Binding Proteins and Their Uses
28 Jul 22
The present invention relates to recombinant binding proteins comprising one or more designed ankyrin repeat domains with binding specificity for coronavirus spike proteins, nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of coronavirus diseases, particularly diseases caused by SARS-CoV-2.
Patrick AMSTUTZ, Valerie Perrine CALABRO, Marcel WALSER
Filed: 11 Feb 22
Utility
Recombinant binding proteins and their use
17 May 22
New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.
Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
Filed: 2 Nov 18
Utility
Designed Ankyrin Repeat Domains with Altered Surface Residues
3 Mar 22
The present invention relates to designed ankyrin repeat domains with altered surface residues, as well as to proteins comprising such a designed ankyrin repeat domain, nucleic acids encoding such domains or proteins, methods of preparing such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.
Kaspar BINZ, Johannes SCHILLING, Patrik FORRER, Victor LEVITSKY, Natalia VENETZ, Marcel WALSER
Filed: 12 Aug 21
Utility
Multispecific Proteins
23 Dec 21
The present disclosure relates to multispecific proteins comprising designed ankyrin repeat domains with binding specificity for different targets, such as, e.g.
Nicolo RIGAMONTI, Clara DOMKE, Valérie Perrine CALABRO, Pamela Anna TRAIL SMITH, Victor LEVITSKY, Niina Elisabet VEITONMÄKI
Filed: 14 May 21
Utility
Novel Ankyrin Repeat Binding Proteins and Their Uses
11 Nov 21
The present invention relates to recombinant binding proteins comprising one or more designed ankyrin repeat domains with binding specificity for coronavirus spike proteins, nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of coronavirus diseases, particularly diseases caused by SARS-CoV-2.
Patrick AMSTUTZ, Valerie Perrine CALABRO, Marcel WALSER
Filed: 6 May 21
Utility
Recombinant Binding Proteins Targeting HER2 and Serum Albumin, and Their Uses
6 May 21
New recombinant binding proteins, comprising designed ankyrin repeat domain(s) with binding specificity for HER2, and comprising designed ankyrin repeat domain(s) with binding specificity for serum albumin, are disclosed, as well as nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such recombinant binding proteins or nucleic acids and the use of such recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.
Clara METZ, Ulrike FIEDLER, Ignacio DOLADO, Heike Maria STROBEL
Filed: 22 Jun 20
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first